Acute Respiratory Distress Syndrome (ARDS) - Market Insights, Epidemiology and Market Forecast – 2025
This report can be delivered to the clients within 5 Business Days
DelveInsight’s “Acute Respiratory Distress Syndrome (ARDS) - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Acute Respiratory Distress Syndrome (ARDS) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.
This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Acute Respiratory Distress Syndrome (ARDS). It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Acute Respiratory Distress Syndrome (ARDS) for 7 major markets.
The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the
Report highlights the frontrunners, the drivers and barriers for the Acute Respiratory Distress Syndrome (ARDS) market, as well as treatment algorithm, current treatments & advancements are included.
The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Acute Respiratory Distress Syndrome (ARDS), providing an in-depth analysis of emerging therapies which will create an impact through their launch.
According to DelveInsight, the forecasted patient population of Acute Respiratory Distress Syndrome (ARDS) for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Acute Respiratory Distress Syndrome (ARDS) 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Acute Respiratory Distress Syndrome (ARDS) market from inside out, with transparency into the calculated patient forecasting data and estimated market size.
KEY COVERAGE
DelveInsight’s “Acute Respiratory Distress Syndrome (ARDS) - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Acute Respiratory Distress Syndrome (ARDS) for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.
This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Acute Respiratory Distress Syndrome (ARDS). It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Acute Respiratory Distress Syndrome (ARDS) for 7 major markets.
The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the
Report highlights the frontrunners, the drivers and barriers for the Acute Respiratory Distress Syndrome (ARDS) market, as well as treatment algorithm, current treatments & advancements are included.
The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Acute Respiratory Distress Syndrome (ARDS), providing an in-depth analysis of emerging therapies which will create an impact through their launch.
According to DelveInsight, the forecasted patient population of Acute Respiratory Distress Syndrome (ARDS) for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Acute Respiratory Distress Syndrome (ARDS) 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Acute Respiratory Distress Syndrome (ARDS) market from inside out, with transparency into the calculated patient forecasting data and estimated market size.
KEY COVERAGE
- Understanding historical and forecasted epidemiological data for Acute Respiratory Distress Syndrome (ARDS) covering 7MM from 2015-2025.
- Segment level epidemiology and market split for Acute Respiratory Distress Syndrome (ARDS).
- The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Acute Respiratory Distress Syndrome (ARDS).
- The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Acute Respiratory Distress Syndrome (ARDS) market trends.
- Thorough market distribution based on market share for Acute Respiratory Distress Syndrome (ARDS).
- The report will help in developing business strategies by understanding trends shaping and driving the Acute Respiratory Distress Syndrome (ARDS) market.
- To understand the future market competition in the Acute Respiratory Distress Syndrome (ARDS) market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Acute Respiratory Distress Syndrome (ARDS) in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
- Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
1. REPORT INTRODUCTION
2. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share Distribution of Acute Respiratory Distress Syndrome (ARDS) for 7 MM in 2016
2.2. Total Market Share Distribution of Acute Respiratory Distress Syndrome (ARDS) for 7 MM in 2025
3. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1.1. United States
4.1.1.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in United Kingdom
5. TREATMENT ALGORITHM
5.1.1. Treatment Guidelines/Practices
6. MARKETED DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. EMERGING THERAPIES
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. OVERVIEW OF TOTAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET (2016 & 2025)
9. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) : COUNTRY-WISE MARKET ANALYSIS
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. MARKET DRIVERS
11. MARKET RESTRAINTS
12. APPENDIX
13. REPORT METHODOLOGY
14. CONSULTING SERVICES
15. DISCLAIMER
16. ABOUT DELVEINSIGHT
2. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET OVERVIEW AT A GLANCE
2.1. Total Market Share Distribution of Acute Respiratory Distress Syndrome (ARDS) for 7 MM in 2016
2.2. Total Market Share Distribution of Acute Respiratory Distress Syndrome (ARDS) for 7 MM in 2025
3. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1.1. United States
4.1.1.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Acute Respiratory Distress Syndrome (ARDS) in United Kingdom
5. TREATMENT ALGORITHM
5.1.1. Treatment Guidelines/Practices
6. MARKETED DRUGS FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status
7. EMERGING THERAPIES
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase
8. OVERVIEW OF TOTAL ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) MARKET (2016 & 2025)
9. ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) : COUNTRY-WISE MARKET ANALYSIS
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)
10. MARKET DRIVERS
11. MARKET RESTRAINTS
12. APPENDIX
13. REPORT METHODOLOGY
14. CONSULTING SERVICES
15. DISCLAIMER
16. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in United States (2015-2025)
Table 2: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Germany (2015-2025)
Table 3: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in France (2015-2025)
Table 4: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Spain (2015-2025)
Table 6: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Italy (2015-2025)
Table 7: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Japan (2015-2025)
Table 8: List of Marketed Drugs for Acute Respiratory Distress Syndrome (ARDS)
Table 9: List of Pipeline Phase III Drugs for Acute Respiratory Distress Syndrome (ARDS)
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 17: Germany Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 18: France Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 20: Spain Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 21: Italy Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 22: Japan Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 1: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in United States (2015-2025)
Table 2: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Germany (2015-2025)
Table 3: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in France (2015-2025)
Table 4: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Spain (2015-2025)
Table 6: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Italy (2015-2025)
Table 7: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Japan (2015-2025)
Table 8: List of Marketed Drugs for Acute Respiratory Distress Syndrome (ARDS)
Table 9: List of Pipeline Phase III Drugs for Acute Respiratory Distress Syndrome (ARDS)
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 17: Germany Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 18: France Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 20: Spain Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 21: Italy Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Table 22: Japan Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
LIST OF FIGURES
Figure 1: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in United States (2015-2025)
Figure 2: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Germany (2015-2025)
Figure 3: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in France (2015-2025)
Figure 4: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Spain (2015-2025)
Figure 6: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Italy (2015-2025)
Figure 7: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Acute Respiratory Distress Syndrome (ARDS)
Figure 9: List of Pipeline Phase III Drugs for Acute Respiratory Distress Syndrome (ARDS)
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 17: Germany Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 18: France Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 20: Spain Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 21: Italy Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 22: Japan Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
KEY COMPANIES
Figure 1: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in United States (2015-2025)
Figure 2: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Germany (2015-2025)
Figure 3: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in France (2015-2025)
Figure 4: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Spain (2015-2025)
Figure 6: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Italy (2015-2025)
Figure 7: Diagnosed Cases Acute Respiratory Distress Syndrome (ARDS) in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Acute Respiratory Distress Syndrome (ARDS)
Figure 9: List of Pipeline Phase III Drugs for Acute Respiratory Distress Syndrome (ARDS)
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 17: Germany Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 18: France Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 20: Spain Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 21: Italy Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
Figure 22: Japan Market Size of Acute Respiratory Distress Syndrome (ARDS) in USD, Million (2015-2025)
KEY COMPANIES
